Patient and disease characteristics
| Characteristic . | N = 39 . |
|---|---|
| Age, median (range), y | 54 (28-79) |
| Sex (%) | |
| Female | 19 (49) |
| Male | 20 (51) |
| Ann Arbor stage (%) | |
| III | 13 (33) |
| IV | 26 (67) |
| ECOG performance status score (%) | |
| 0 | 29 (74) |
| 1 | 10 (26) |
| B-symptoms present (%) | 9 (23) |
| Bulk of ≥7 cm (%) | 9 (23) |
| Extranodal sites, ≥1 (%) | 29 (74) |
| FL histological grade (%) | |
| 1-2 | 30 (77) |
| 3A | 8 (21) |
| Treatment eligibility (%) | |
| GELF criteria present∗ | 31 (80) |
| Rapid disease progression in prior 3 mo | 6 (15) |
| Other (symptomatic lymphadenopathy or painful bone lesions) | 2 (5) |
| FLIPI risk score (%) | |
| Low risk (0-1) | 10 (26) |
| Intermediate risk (2) | 22 (56) |
| High risk (3) | 7 (18) |
| Characteristic . | N = 39 . |
|---|---|
| Age, median (range), y | 54 (28-79) |
| Sex (%) | |
| Female | 19 (49) |
| Male | 20 (51) |
| Ann Arbor stage (%) | |
| III | 13 (33) |
| IV | 26 (67) |
| ECOG performance status score (%) | |
| 0 | 29 (74) |
| 1 | 10 (26) |
| B-symptoms present (%) | 9 (23) |
| Bulk of ≥7 cm (%) | 9 (23) |
| Extranodal sites, ≥1 (%) | 29 (74) |
| FL histological grade (%) | |
| 1-2 | 30 (77) |
| 3A | 8 (21) |
| Treatment eligibility (%) | |
| GELF criteria present∗ | 31 (80) |
| Rapid disease progression in prior 3 mo | 6 (15) |
| Other (symptomatic lymphadenopathy or painful bone lesions) | 2 (5) |
| FLIPI risk score (%) | |
| Low risk (0-1) | 10 (26) |
| Intermediate risk (2) | 22 (56) |
| High risk (3) | 7 (18) |
ECOG, Eastern Cooperative Oncology Group.
GELF criteria includes: any tumor mass of >7 cm diameter, ≥3 nodal sites (each >3 cm diameter), B-symptoms, splenomegaly, compression syndrome, serous effusion, leukemic phase, peripheral blood cytopenias, LDH, or β-2-microglobulin above the upper limit of normal.